“SGLT2i Add-On Treatment Effectively Lowers HbA1c in T2DM Patients, but with Increased Adverse Event Risk”

https://pubmed.ncbi.nlm.nih.gov/38114614

SGLT2i add-on treatment effectively and safely lowers HbA1c levels and increases the proportion of patients achieving HbA1c < 7% in T2DM patients with dual or triple treatment in a real-world setting, with a slightly elevated risk of certain adverse events.